Conor Allison is a leading voice in the wearable technology sector, serving as a key expert at Wareable where he bridges the gap between complex biometric data and everyday fitness performance. With years of experience testing everything from AI-driven recovery tools to advanced health sensors, he has a deep understanding of how hardware and software intersect to improve human longevity. His expertise is particularly vital now as the industry shifts from general activity tracking toward specialized, medical-grade insights. In this conversation, we explore the latest breakthroughs in female-focused health tech, discussing how dynamic biomarker analysis and algorithmic personalization are finally addressing the unique physiological needs of women.
How do markers like Anti-Müllerian Hormone and Thyroid Peroxidase Antibodies clarify life stages like perimenopause? In what ways does adjusting these benchmarks according to a person’s specific cycle phase provide a more accurate health picture than a one-size-fits-all static blood test?
The inclusion of Anti-Müllerian Hormone (AMH) and Thyroid Peroxidase Antibodies (TPOAb) is a game-changer because these markers act as specific windows into ovarian reserve and thyroid health, which are often the first things to fluctuate during perimenopause. Traditionally, a woman might get a blood test on a random Tuesday, and if her levels look “normal” by male-centric standards, her symptoms are dismissed. By integrating these 11 specialized biomarkers with continuous wearable data, we move away from that static snapshot and toward a cycle-aware model. This means the app automatically recalibrates what “optimal” looks like based on whether a user is in their follicular or luteal phase. It prevents the misinterpretation of data, ensuring that a hormonal dip isn’t mistaken for a health crisis, but rather recognized as a natural part of a shifting rhythm.
When monitoring trends in cycle variability and predicting upcoming hormonal symptoms, what specific steps should be taken to modify training? How do you use dynamic date windows to anticipate recovery needs, and what metrics suggest a need for immediate lifestyle adjustments?
Monitoring trends in cycle length and variability allows an athlete to stop reacting to fatigue and start anticipating it. When the system identifies a dynamic date window for an upcoming period, it serves as a prompt to scale back high-intensity training and prioritize sleep hygiene before the symptoms actually hit. If the data shows a significant trend of irregular patterns or increased symptom severity, those are the metrics that suggest a need for immediate lifestyle intervention or a consultation with a physician. We are moving toward a model where you don’t just log a period after it starts; you use historical data to adjust your strain targets and recovery protocols days in advance. This proactive approach helps avoid the “prolonged issues” that occur when you push through a phase of the cycle where your body is physiologically primed for rest.
Algorithms must account for the complexities of hormonal birth control and irregular cycles to stay relevant. What are the technical difficulties in modeling these shifts, and how does this level of data personalization change the way women manage chronic conditions like thyroid dysfunction?
The primary technical difficulty lies in the fact that hormonal birth control often masks or alters the natural biometric signals, such as basal body temperature or heart rate variability, that algorithms usually rely on. To solve this, new research-backed white papers have been developed to detail how algorithms can be adjusted for variable cycles and synthetic hormones. For women managing chronic conditions like thyroid dysfunction, this personalization is revolutionary because it separates the “noise” of medication or birth control from the “signal” of their actual thyroid health. Instead of guessing why they feel sluggish, they can look at their specific TPOAb levels in the context of their cycle. It empowers users to have data-driven conversations with their doctors, backed by a comprehensive health platform rather than a series of disconnected lab reports.
Nutrient sufficiency, specifically Vitamin B12 and Folate, is often overlooked in general screenings. How does tracking these alongside ovarian reserve markers impact long-term wellness, and what is the process for turning these lab insights into actionable daily habits or dietary changes?
Tracking Vitamin B12 and Folate is essential because these nutrients are the foundational building blocks for energy metabolism and reproductive health. When you see these results alongside AMH or Progesterone, you start to see the “why” behind your daily recovery scores and overall wellness. The process of turning these insights into action involves taking those 11 targeted biomarkers and translating them into tangible dietary shifts or supplementation strategies. For instance, if the lab work shows a deficiency in Folate during a specific life stage, the user can immediately pivot their nutrition to support their body’s needs. It’s about closing the loop between a clinical blood draw and the daily habits that actually move the needle on a person’s long-term health trajectory.
With advanced lab testing and biomarker analysis often rolling out in specific regions first, what are the primary hurdles to achieving global standardization? How do localized healthcare regulations and data collection challenges impact the timeline for making these insights accessible to an international audience?
The biggest hurdle to global standardization is the sheer complexity of localized healthcare regulations and the logistical nightmare of coordinating blood draws across different legal jurisdictions. In the US, the rollout of these specialized panels is set for April, but international users often face a “protracted worldwide rollout” because each country has different standards for how biometric data must be handled. We saw this previously with the baseline testing suites, and it’s likely that many international markets won’t see these women-focused panels until 2026. Data collection challenges also play a role, as the AI models need to be trained on diverse populations to ensure the “dynamic insights” are accurate for everyone, regardless of their geographic location. It’s a slow process, but the goal is to ensure that when these features do go global, they are as clinically backed and accurate as possible.
What is your forecast for women’s health technology?
My forecast is that women’s health technology will move entirely away from being a “niche” category and become the gold standard for personalized medicine. We are seeing a massive shift where major players are finally investing in AI models specifically trained on women’s health studies to serve a demographic that has been historically underserved in medical research. In the next few years, the integration of continuous wearable metrics with periodic, cycle-aware blood work will become the expected norm for any comprehensive health platform. We will see sensors that can track even more specific hormonal fluctuations in real-time, effectively ending the era of the “static snapshot” and replacing it with a 24/7, high-definition map of female physiology. The ultimate goal is to turn this mountain of information into clear, automated actions that allow every woman to navigate her life stages with total confidence and clarity.
